
**Johnson & Johnson (JNJ) Stock: Q2 Earnings Top Estimates, Full-Year Outlook Raised**
Johnson & Johnson (JNJ) has reported its second-quarter 2025 earnings, surpassing analyst expectations and increasing its full-year outlook. The pharmaceutical giant’s impressive performance has led to a significant boost in investor sentiment, with the company’s stock price rising by over 2% in premarket trading.
The Q2 adjusted EPS came in at $2.77, exceeding estimates of $2.66. Meanwhile, reported EPS was $2.29, outperforming expectations once again. This exceptional earnings report has instilled optimism among investors, with the company’s revenue rising by an impressive 5.8% year-over-year to $23.74 billion, comfortably beating forecasts.
The company’s full-year outlook now stands at a range of $93.2-$93.6 billion in terms of revenue and an EPS projection between $10.80 and $10.90. This upward revision has provided significant tailwinds for the stock, with JNJ shares experiencing a 7% year-to-date gain.
The company’s performance is largely attributed to its robust pipeline of therapies and strong business lines within MedTech. In addition, CEO Joaquin Duato emphasized the importance of their pipeline’s potential in driving momentum for the remainder of the year.
“Game-changing” programs are on the horizon, with notable advancements in oncology, neuroscience, dermatology, and surgery. The company reasserted its commitment to U.S. manufacturing, allocating $55 billion over four years towards this goal.
As a result, investors seem confident that the latter half of 2025 could unlock even greater gains for JNJ shares, fueled by impending drug approvals and innovation within MedTech.
Source: coincentral.com